Bank of America Corp DE Sells 1,935,982 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Bank of America Corp DE decreased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 32.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 4,013,436 shares of the company’s stock after selling 1,935,982 shares during the period. Bank of America Corp DE owned about 0.35% of Teva Pharmaceutical Industries worth $88,456,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Oarsman Capital Inc. bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $44,000. Ameliora Wealth Management Ltd. bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $66,000. IFP Advisors Inc grew its holdings in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after purchasing an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its holdings in shares of Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock worth $96,000 after purchasing an additional 949 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $16.94 on Monday. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80. The stock has a market cap of $19.21 billion, a PE ratio of -11.68, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The company’s fifty day moving average price is $15.18 and its 200-day moving average price is $17.44.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Teva Pharmaceutical Industries’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.48 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on TEVA shares. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, April 23rd. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a report on Monday, April 28th. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, Barclays cut their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Buy” and an average target price of $23.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.